Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
 

Life Sciences

full industries list
Life Sciences Image
News
Events
Litigation Blog
Hatch-Waxman

Fish attorneys have served as leading advisors to pioneers in the pharmaceutical, biotechnology, and life sciences fields for more than a century. For three consecutive years, we have been named the top US law firm for life sciences and biotechnology IP work by Managing Intellectual Property. Clients choose Fish because of the technical and scientific expertise of our internationally recognized attorneys.

Large and small companies, along with academic and research institutions, turn to Fish’s team to protect their most valuable innovations. We offer biotechnology and pharmaceutical clients services that include:

Our industry-leading litigation practice regularly represents the world’s largest branded pharmaceutical companies in high-stakes, high-risk litigation. Drug makers trust our litigators to handle their blockbuster Hatch-Waxman, BPCIA, and competitor litigation matters because they possess the unique combination of technical, legal, and industry expertise necessary for success.

Examples of our biotechnology and pharmaceutical work include:

  • Patenting groundbreaking life sciences innovations, including tissue engineering, therapeutic agents and methods, antibodies, and genetically engineered animals
  • Gaining FDA approvals for small molecule drugs and biologics, including gene and cell therapies, antibiotics, immunologics, and anti-anxiety medications
  • Conducting IP due diligence on billions of dollars in deal value for pharmaceutical investments, mergers, and acquisitions
  • Representing dozens of biotechnology and pharmaceutical clients in patent infringement litigation
  • Litigating ANDA cases on behalf of branded pharmaceuticals
  • Representing biotechnology and pharmaceutical companies in post-grant proceedings at the PTAB, as well as coordinating post-grant and district court litigation strategies

Notable Wins

Fish Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead

Fish won a unanimous Federal Circuit opinion today that affirmed its June 2016 post-trial wipe-out of a $200 million jury verdict against client Gilead Sciences, Inc. after proving Merck had forfeited its right to assert its hepatitis C drug patents against Gilead because of litigation and business misconduct constituting “unclean hands.”

Read more about this precedential opinion here and here.

Fish Wipes Out $2.5B Patent Verdict Against Gilead Sciences

Fish & Richardson won a motion for Judgment as a Matter of Law (JMOL) that reversed a $2.5 billion jury verdict against its client Gilead Sciences Inc. in federal court in Delaware.

Read about this historic win here and here.

Recent Webinars

2022

2021

2020

2019

2018

Mayo/Myriad Tracker

Search Fish Team

Search by Letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
No matches
Life Sciences

Life Sciences Team

What's Trending in Life Sciences

Filter by
News
September 15, 2022
What to Know About the USPTO’s Duty of Candor Guidance Regarding FDA Submissions
Legal Alerts
Event
October 11th, 2022 | 4:00 pm CET
Life Sciences Strategy Summit on IP & Exclusivity
Speaking Engagement
Conference/Convention
Sponsorship
News
September 9, 2022
Fish & Richardson Wins Six 2022 LMG Life Sciences Awards, Including “IP Firm of the Year”
Press Release
Recognition
News
Event
September 29th, 2022 | 8:00 am EDT
Kisaco Research Women's Health Innovation Summit
Sponsorship
Event
October 5th, 2022 | 1:30 pm EDT
Webinar | Preparing for Future Litigation: Strategies for Start-Ups
Webinar
News
August 15, 2022
Fish & Richardson Secures Win for Exela Pharma Sciences in ELCYS® Patent Infringement Litigation
Press Release
News
Event
September 22nd, 2022 | 2:50 pm EDT
Longwood Healthcare Leaders Fall Meeting
Speaking Engagement
Sponsorship
News
July 21, 2022
Fish & Richardson Featured in Nine Categories of the LMG Life Sciences Awards 2022 Shortlists
Press Release
Announcements
Recognition
News
News
July 11, 2022
Principal Kelly Del Dotto Interviewed by The Pharma Letter for "Regulatory Q&A: U.S. Patent Law and The Orange Book"
Articles
Event
August 3rd, 2022 | 1:30 pm EDT
Webinar | Post-Grant Considerations: What Start-Ups Need to Know
Webinar
Event
July 13th, 2022 | 1:30 pm EDT
Webinar | Patent Portfolio Management: Strategies for Navigating Due Diligence for Startups
Webinar
Event
June 21st, 2022 | 4:05 pm EDT
LSX USA World Congress 2022 | Biotech Startup/Early-Stage CEO Forum
Speaking Engagement
Sponsorship
load more topics